
RenovoRx rose 18.8% from $0.80 to $0.95, ahead of the S&P 500's +11.2%. Its worst day was Aug 17 (−14.3%), and its low came Nov 19 at $0.73.
Nov 17, 2025 – Nov 16, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
RenovoRx closed at its lowest level of the year, 8.9% below where the year started.
−6.4% · S&P 500 +0.4%
New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx’s TAMP Therapy Platform as a Targeted Drug-Delivery ApproachData Shows a PK Profile that May
Story events cover the past 12 months · Times ET
+13.9% · S&P 500 0.0%
RenovoRx shares rose 16.5%, while the S&P 500 rose 1.0%.
+16.5% · S&P 500 +1.0%
EPS of $-0.08 beat the $-0.08 estimate on $238,000.00 revenue (est. $451,850.00).
−5.6% · S&P 500 +2.9%
EPS of $-0.08 beat the $-0.08 estimate on $563,000.00 revenue (est. $470,600.00); FY revenue guidance of $3.0M–$4.0M against the $3.2M consensus.
−4.1% · S&P 500 −1.2%
EPS of $-0.05 beat the $-0.08 estimate on $909,000.00 revenue (est. $709,000.00); FY revenue guidance of $3.8M–$4.3M against the $3.2M consensus.
+12.5% · S&P 500 +0.7%
RenovoRx shares rose 13.6%, while the S&P 500 rose 0.3%.
+13.6% · S&P 500 +0.3%
RenovoRx closed at its highest level of the year, 213.4% above where the year started.
+19.4%, the year's best day, on 4M shares, the year's heaviest volume · S&P 500 +0.4%
EPS of $-0.07 missed the $-0.05 estimate on $1.1M revenue (est. $1.1M); FY revenue guidance of $3.8M–$4.3M against the $3.9M consensus.
−5.0% · S&P 500 +0.3%
Where it ended: a close of $0.95 on Nov 16, 2026.
Nothing in the past 12 months.
All RNXT dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RNXT and SPY from Benzinga historical bars. Not investment advice.